Craig Hallum Boosts NeoGenomics (NASDAQ:NEO) Price Target to $42.00

NeoGenomics (NASDAQ:NEO) had its price target lifted by Craig Hallum from $36.00 to $42.00 in a research note published on Wednesday morning, The Fly reports. The brokerage currently has a buy rating on the medical research company’s stock.

A number of other research firms have also commented on NEO. Benchmark raised their price target on shares of NeoGenomics from $35.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday. Zacks Investment Research raised shares of NeoGenomics from a hold rating to a buy rating and set a $41.00 price target on the stock in a research report on Wednesday. BidaskClub raised shares of NeoGenomics from a buy rating to a strong-buy rating in a research report on Friday, July 3rd. CIBC lowered shares of NeoGenomics to a neutral rating and lowered their price target for the stock from $11.00 to $9.00 in a research report on Friday, May 15th. Finally, SVB Leerink increased their price objective on shares of NeoGenomics from $35.00 to $45.00 and gave the stock an outperform rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. NeoGenomics presently has a consensus rating of Buy and a consensus price target of $35.80.

Shares of NEO opened at $38.23 on Wednesday. The firm has a market capitalization of $4.03 billion, a PE ratio of -764.60 and a beta of 0.76. The company’s 50-day moving average is $32.69 and its 200-day moving average is $29.86. NeoGenomics has a fifty-two week low of $18.52 and a fifty-two week high of $38.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 6.79 and a quick ratio of 2.88.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. NeoGenomics had a negative net margin of 1.33% and a positive return on equity of 0.73%. The business had revenue of $86.90 million for the quarter, compared to analyst estimates of $86.55 million. During the same period last year, the firm earned $0.07 earnings per share. NeoGenomics’s revenue for the quarter was down 14.6% compared to the same quarter last year. Analysts predict that NeoGenomics will post -0.1 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of NEO. C M Bidwell & Associates Ltd. acquired a new stake in shares of NeoGenomics in the 1st quarter valued at approximately $30,000. Carroll Financial Associates Inc. acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at approximately $31,000. Global Retirement Partners LLC boosted its stake in shares of NeoGenomics by 27.1% in the 1st quarter. Global Retirement Partners LLC now owns 2,110 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 450 shares in the last quarter. Jacobi Capital Management LLC boosted its stake in shares of NeoGenomics by 70.1% in the 2nd quarter. Jacobi Capital Management LLC now owns 3,401 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 1,401 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC boosted its stake in shares of NeoGenomics by 108.3% in the 2nd quarter. Prime Capital Investment Advisors LLC now owns 2,083 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 1,083 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Story: S&P 500 Index

The Fly

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.